钙镁合剂和甲钴胺预防奥沙利铂所致神经毒性疗效比较

杨武; 喻永龙; 王新帅; 朱西平; 张振华

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

钙镁合剂和甲钴胺预防奥沙利铂所致神经毒性疗效比较

杨武 , 喻永龙 , 王新帅 , 朱西平 , 张振华

文章导航 > 蚌埠医学院学报 > 2013, 37 > 1: (37-40)

引用本文:

Citation:

钙镁合剂和甲钴胺预防奥沙利铂所致神经毒性疗效比较

1.
1. 安徽省宁国市人民医院肿瘤科, 242300;
2.
2. 河南科技大学第一附属医院肿瘤中心, 河南洛阳 471003

作者简介: 杨武(1977-)，男，主治医师．

基金项目:

Efficacy comparison of calcium-magnesium infusion and mecobalamin to prevent the neurotoxicity induced by oxaliplatin

1.
1. Department of Oncology, Ningguo People′s Hospital, Ningguo Anhui 242300;
2.
2. Department of Oncology, The First Affiliated Hospital of Henan Technology University, Luoyang Henan 471003, China

摘要: 目的：评估钙镁合剂和甲钴胺对奥沙利铂引起神经毒性的预防作用。方法：采用随机、安慰剂对照的方法，将接受奥沙利铂+氟尿嘧啶+亚叶酸钙方案化疗的90例大肠癌患者随机分为3组，分别给予钙镁合剂、甲钴胺和生理盐水。利用奥沙利铂专用神经毒性分级和神经症状评分(NSS)观察患者神经毒性发生率及严重程度。结果：单纯化疗组、钙镁合剂组、甲钴胺组急性神经毒性发生率分别为93．1％、66．7％、65．5％，差异有统计学意义(P0．05)。慢性神经毒性，化疗3周期评价时3组之间有统计学意义(P0．01)。钙镁合剂和甲钴胺组Ⅰ～Ⅲ度神经毒性均低于单纯化疗组(P0．01和P0．05)，钙镁合剂组和甲钴胺组差异无统计学意义(P0．05)。化疗6周期时3组差异有统计学意义(P0．05)，钙镁合剂组神经毒性发生率低于单纯化疗组(P0．05)，但甲钴胺组和单纯化疗组差异无统计学意义(P0．05)。根据NSS评分，单纯化疗组3周期、6周期时评分均高于其他2组(P0．01和P0．05)，而钙镁合剂和甲钴胺组差异无统计学意义(P0．05)．结论：钙镁合剂和甲钴胺均能降低奥沙利铂神经毒性的发生率和程度。
- 肿瘤/药物疗法 /
- 奥沙利铂 /
- 神经毒性 /
- 钙镁合剂 /
- 甲钴胺
Abstract: Objective: To evaluate the effects of calcium-magnesium ( Ca/Mg) infusion and mecobalamin on preventing the neurotoxicity induced by oxaliplatin. Methods:Taking the method of random and placebo control,90 patients with colon cancer treated with oxaliplatin + fluorouracil + calcium folinate chemotherapy were randomly divided into three groups which were treated with Ca/Mg infusion, mecobalamin and normal saline, respectively. According to Sanofisyn thelabo and neuropathy symptom score (NSS),the neurotoxicity incidence and severity of all patients were observed. Results:The actue neurotoxicity incidence of normal saline,Ca/Mg infusion and mecobalamin group were 27 cases(93. 1%),20 cases(66.7%) and 19 cases(65. 5%),respectively,which differences were statistical significance(P0.05). There were significant difference between the chronic neurotoxicity of three groups after 3 cycles of chemotherapy(P0. 01). TheⅠ-Ⅲ degree neurotoxicity of Ca/Mg infusion and mecobalamin groups were no difference(P 0.05),but which were lower than that of chemotherapy group(P0.01 to P0.05). After 6 cycles of chemotherapy,there were significant differences between the incidence of neurotoxicity of three groups(P0.05),the neurotoxicity of Ca/Mg infusion group was lower than that of chemotherapy group(P0.05),and the differences of mecobalamin and chemotherapy groups were not statistical significance(P0.05). The NSS score of chemotherapy group was higher than that of other two groups after 3 and 6 cycles of chemotherapy(P0.01 and P0.05),but for other two groups had no differences(P0.05). Conclusions:Ca/Mg infusion and mecobalamin can decrease the incidence and intensity of neurotoxicity induced by oxaliplatin.
- tumor/drug therapy /
- oxaliplatin /
- neurotoxicity /
- calcium-magnesium infusion /
- mecobalamin

[1]	Holmes J,Stanko J,Varchenko M,et al. Comparative neurotoxicity of oxaliplatin,cisplatin,and ormaplatin in a Wistar rat model[J].Toxicol Sci,1998,46(2):342－351.
[2] Grolleau F,Gamelin L,Boisdron-Celle M,et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. J Neurophysiol,2001,85 (5):2293－2297.
[3] Webster RG,Brain KL,Wilson RH,et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels[J]. Br J Pharmacol,2005,146(7):1027－1039.
[4] Gamelin L,Boisdron-Celle M,Delva R,et al. Prevention of oxaliplatin-related neurotoxicity by calcium and
[5]	magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer[J]. Clin Cancer Res,2004,10(12):4055－4061.
[5] Armstrong CM,Cota G. Calcium block of Na+ channels and its effect on closing rate[J]. Proc Natl Acad Sci U S A,1999,96(7):4154－4157.
[6] Adelsberger H,Quasthoff S,Grosskreutz J,et al. The chemotherapeutic oxaliplatin alters voltage-gated Na( +) channel kinetics on rat sensory neurons[J]. Eur J Pharmacol,2000,406(1):25－32.
[7] Lajer H,Daugaard G. Cisplatin and hypomagnesemia[J]. Cancer Treat Rev,1999,25(1):47－58.
[8] Hochster HS,Grothey A,Childs B,et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity[J]. J Clin Oncol,2007,25(25):4028－4029.
[9] Grothey A,Nikcevich DA,Sloan JA,et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer:NCCTG N04C7[J]. J Clin Oncol,2011,29(4):421－427.
[10] 姜雅秋,刘国良,王秋月. 弥可保治疗糖尿病周围神经病变的疗效观察[J]. 辽宁医学杂志,1998,12(2):100－101.

[1]	盛桂凤 , 毕延智 , 董益忠 , 张亚平 , 宋红蕾 , 徐建忠 . 葡萄糖酸钙防治改良FOLFOX4方案治疗晚期胃肠肿瘤神经毒性观察. 蚌埠医学院学报, 2009, 34(12): 1106-1108.
[2]	韩啸 . 多西他赛联合奥沙利铂治疗晚期非小细胞肺癌34例临床观察. 蚌埠医学院学报, 2008, 33(5): 535-537.
[3]	张泗兰 . 前列地尔与甲钴胺合用治疗糖尿病周围神经病变疗效观察. 蚌埠医学院学报, 2005, 30(6): 549-550.
[4]	王影 . 康复新防治奥沙利铂所致周围神经毒性的效果观察. 蚌埠医学院学报, 2015, 40(4): 536-537. doi: 10.13898/j.cnki.issn.1000-2200.2015.04.041
[5]	翟云芝 , 郑荣生 . 奥沙利铂联合亚叶酸钙、氟尿嘧啶治疗晚期胃癌. 蚌埠医学院学报, 2005, 30(3): 249-250.
[6]	徐金发 , 潘明 , 鲍瑜 , 陈倩 . 奥沙利铂联合亚叶酸钙/氟尿嘧啶治疗晚期胃癌的临床观察. 蚌埠医学院学报, 2009, 34(5): 417-419.
[7]	王有猛 , 阚庆生 . 奥沙利铂联合氟尿嘧啶/亚叶酸钙方案治疗晚期结直肠癌30例. 蚌埠医学院学报, 2010, 35(9): 926-927.
[8]	胡加海 . 甲钴胺联合盐酸羟考酮缓释片治疗中重度癌性疼痛临床疗效观察. 蚌埠医学院学报, 2015, 39(7): 932-934. doi: 10.13898/j.cnki.issn.1000-2200.2015.07.034
[9]	杨武 , 喻永龙 , 朱西平 , 张振华 . 替吉奥和卡培他滨分别联合奥沙利铂化疗对晚期胃癌疗效观察. 蚌埠医学院学报, 2014, 39(11): 1512-1514.
[10]	何峰 , 张小霞 . 奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响. 蚌埠医学院学报, 2013, 37(9): 1096-1098,1102.
[11]	高洁 , 丁淑琴 , 邓蓉 , 郭普 , 张伦军 , 黄桦 . 奥沙利铂通过p53信号通路抑制肝癌细胞增殖的机制研究. 蚌埠医学院学报, 2018, 43(8): 984-988. doi: 10.13898/j.cnki.issn.1000-2200.2018.08.002
[12]	王有猛 , 阚庆生 . 紫杉醇联合奥沙利铂治疗非小细胞肺癌疗效分析. 蚌埠医学院学报, 2010, 35(10): 1023-1024.
[13]	杨燕 , 王明喜 , 汪子书 , 王俊斌 , 郑荣生 . 奥沙利铂联合吉西他滨治疗晚期原发性肝癌疗效观察. 蚌埠医学院学报, 2015, 40(9): 1158-1160. doi: 10.13898/j.cnki.issn.1000-2200.2015.09.005
[14]	蒋祥德 , 王磊 , 刘友如 , 施朕善 , 徐莹 . 卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌临床观察. 蚌埠医学院学报, 2014, 38(4): 471-473.
[15]	李靖 , 郑旭薇 , 贾建光 , 郭晨旭 , 金鑫 , 钱军 . 人参皂苷Rh2对低浓度的奥沙利铂诱导人胃癌SGC-7901侧群细胞凋亡的增敏作用. 蚌埠医学院学报, 2018, 43(5): 561-566,572. doi: 10.13898/j.cnki.issn.1000-2200.2018.05.001
[16]	王小芳 , 沈梅竹 , 汪济东 , 庞东生 . 简化水化方案预防顺铂肾毒性105例的护理经验. 蚌埠医学院学报, 2004, 29(2): 185-185.
[17]	翟云芝 , 郑荣生 . 去甲长春碱或吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效比较. 蚌埠医学院学报, 2005, 30(5): 400-401.
[18]	殷献录 , 李静 . 小剂量沙利度胺治疗骨髓增生异常综合征21例疗效观察. 蚌埠医学院学报, 2008, 33(2): 176-177.
[19]	吴燕明 , 丁刚 , 丁厚明 . 沙利度胺联合化疗治疗多发性骨髓瘤的临床观察. 蚌埠医学院学报, 2006, 31(5): 497-498.
[20]	杨全良 , 周彤 , 陆宏俊 , 盛桂凤 , 凌扬 . 甘草酸二胺注射液治疗化疗所致药物性肝损害临床疗效观察. 蚌埠医学院学报, 2005, 30(5): 433-434.

点击查看大图

计量

文章访问数: 3550
HTML全文浏览量: 411
PDF下载量: 117
被引次数: 0

钙镁合剂和甲钴胺预防奥沙利铂所致神经毒性疗效比较

作者简介: 杨武(1977-)，男，主治医师．

1. 1. 安徽省宁国市人民医院肿瘤科, 242300;
2. 2. 河南科技大学第一附属医院肿瘤中心, 河南洛阳 471003

收稿日期: 2011-11-11
网络出版日期: 2013-01-15

基金项目:

关键词:

摘要: 目的：评估钙镁合剂和甲钴胺对奥沙利铂引起神经毒性的预防作用。方法：采用随机、安慰剂对照的方法，将接受奥沙利铂+氟尿嘧啶+亚叶酸钙方案化疗的90例大肠癌患者随机分为3组，分别给予钙镁合剂、甲钴胺和生理盐水。利用奥沙利铂专用神经毒性分级和神经症状评分(NSS)观察患者神经毒性发生率及严重程度。结果：单纯化疗组、钙镁合剂组、甲钴胺组急性神经毒性发生率分别为93．1％、66．7％、65．5％，差异有统计学意义(P0．05)。慢性神经毒性，化疗3周期评价时3组之间有统计学意义(P0．01)。钙镁合剂和甲钴胺组Ⅰ～Ⅲ度神经毒性均低于单纯化疗组(P0．01和P0．05)，钙镁合剂组和甲钴胺组差异无统计学意义(P0．05)。化疗6周期时3组差异有统计学意义(P0．05)，钙镁合剂组神经毒性发生率低于单纯化疗组(P0．05)，但甲钴胺组和单纯化疗组差异无统计学意义(P0．05)。根据NSS评分，单纯化疗组3周期、6周期时评分均高于其他2组(P0．01和P0．05)，而钙镁合剂和甲钴胺组差异无统计学意义(P0．05)．结论：钙镁合剂和甲钴胺均能降低奥沙利铂神经毒性的发生率和程度。

English Abstract

Efficacy comparison of calcium-magnesium infusion and mecobalamin to prevent the neurotoxicity induced by oxaliplatin

1. 1. Department of Oncology, Ningguo People′s Hospital, Ningguo Anhui 242300;
2. 2. Department of Oncology, The First Affiliated Hospital of Henan Technology University, Luoyang Henan 471003, China

Received Date: 2011-11-11
Available Online: 2013-01-15

Abstract: Objective: To evaluate the effects of calcium-magnesium ( Ca/Mg) infusion and mecobalamin on preventing the neurotoxicity induced by oxaliplatin. Methods:Taking the method of random and placebo control,90 patients with colon cancer treated with oxaliplatin + fluorouracil + calcium folinate chemotherapy were randomly divided into three groups which were treated with Ca/Mg infusion, mecobalamin and normal saline, respectively. According to Sanofisyn thelabo and neuropathy symptom score (NSS),the neurotoxicity incidence and severity of all patients were observed. Results:The actue neurotoxicity incidence of normal saline,Ca/Mg infusion and mecobalamin group were 27 cases(93. 1%),20 cases(66.7%) and 19 cases(65. 5%),respectively,which differences were statistical significance(P0.05). There were significant difference between the chronic neurotoxicity of three groups after 3 cycles of chemotherapy(P0. 01). TheⅠ-Ⅲ degree neurotoxicity of Ca/Mg infusion and mecobalamin groups were no difference(P 0.05),but which were lower than that of chemotherapy group(P0.01 to P0.05). After 6 cycles of chemotherapy,there were significant differences between the incidence of neurotoxicity of three groups(P0.05),the neurotoxicity of Ca/Mg infusion group was lower than that of chemotherapy group(P0.05),and the differences of mecobalamin and chemotherapy groups were not statistical significance(P0.05). The NSS score of chemotherapy group was higher than that of other two groups after 3 and 6 cycles of chemotherapy(P0.01 and P0.05),but for other two groups had no differences(P0.05). Conclusions:Ca/Mg infusion and mecobalamin can decrease the incidence and intensity of neurotoxicity induced by oxaliplatin.